Boston Scientific reported Q1 2026 net sales of $5.203 billion, up 11.6% reported, with GAAP EPS of $0.90 and adjusted EPS of $0.80, and issued Q2 and FY2026 guidance.
Key takeaways
Net sales $5,203 million, +11.6% reported / 9.4% operational vs Q1 2025.
GAAP net income attributable to common stockholders $1,341 million, $0.90 per share vs $674 million, $0.45 prior year.
Adjusted EPS $0.80 vs $0.75 prior year, within guidance of $0.78-$0.80.